{
  "docId": "019de077-0f5f-77ef-a5cf-60b15fd5a5a5",
  "docSlug": "f1a62332dbdfff6b54feb25498e49e7e",
  "documentTitle": "Matinas BioPharma | Investor Presentation Deck | 29 slides",
  "authorId": "matinas-biopharma",
  "authorName": "Matinas BioPharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 14,
  "pageCount": 29,
  "prevPage": 13,
  "nextPage": 15,
  "slideType": "problem_statement",
  "function": "frame_problem",
  "density": "overcrowded",
  "nDataPoints": 2,
  "notes": "The slide highlights the limitations of current first-line azole treatments and identifies a specific patient sub-segment with high unmet need.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de077-0f5f-77ef-a5cf-60b15fd5a5a5/14",
  "deckHref": "/decks/019de077-0f5f-77ef-a5cf-60b15fd5a5a5",
  "deckJsonHref": "/decks/019de077-0f5f-77ef-a5cf-60b15fd5a5a5.json",
  "deckAnchorHref": "/decks/019de077-0f5f-77ef-a5cf-60b15fd5a5a5#slide-14",
  "components": [
    {
      "bbox": {
        "h": 0.35,
        "w": 0.2,
        "x": 0.76,
        "y": 0.345
      },
      "kind": "image",
      "text": "Microscopic image of Aspergillus",
      "attrs": null,
      "subkind": "photo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "35fd8131-536d-46db-9dfe-49c82e3c843a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.7,
        "x": 0.03,
        "y": 0.37
      },
      "kind": "list",
      "text": "IDSA Guidelines recommend treatment with mold-active azoles as first-line treatment for 6-12 weeks. Azole use requires fungal expertise to manage toxicities and significant DDIs that can limit duration of use. Resistance to azoles is increasing globally. Breakthrough IA now being reported in patients receiving antifungal prophylaxis (azoles). Failures attributed to non-compliance, poor absorption, DDIs, or infection with drug-resistant Aspergillus species.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b220851d-63fc-4d65-ab32-842bc324042c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.18,
        "w": 0.7,
        "x": 0.03,
        "y": 0.18
      },
      "kind": "list",
      "text": "IA is a serious, life-threatening fungal infection that occurs primarily in severely immunocompromised patients with hematologic malignancies and transplant recipients. ~15,000 new cases per year in the U.S. WHO, CDC, and FDA all consider it a critical priority and a global public health concern.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b710783b-6490-41fb-90fc-148e430584e6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.7,
        "x": 0.03,
        "y": 0.63
      },
      "kind": "list",
      "text": "Unmet medical need highest in IA patients who cannot take azoles. ~3,000-5,000 cases per year in the U.S. Include patients with resistance, intolerance, DDIs, breakthrough infections. No other good long-term oral options. Rare disease/orphan commercial opportunity.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d3e22e10-4814-4c57-9673-d0e9bf887609",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.2,
        "x": 0.76,
        "y": 0.75
      },
      "kind": "source-note",
      "text": "Bazaz R et al. Pharmaceutical Journal 2019",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dc970b1f-a969-42e4-88d0-eeba01894d16",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.94,
        "x": 0.03,
        "y": 0.05
      },
      "kind": "title",
      "text": "High Unmet Medical Need in Invasive Aspergillosis (IA) with Limited Treatment Options",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dadd0e17-5663-4ae3-953c-d88f16d5e2f3",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Problem Statement Canvas",
      "slug": "problem-statement-canvas",
      "agent": "Architect",
      "layer": "slide",
      "matchId": "69c9c97a-e732-4b13-b8f2-1b2bd7c00d6c",
      "evidence": "list/bullet: IDSA Guidelines recommend treatment with mold-active azoles as first-line treatment for 6-12 weeks. Azole use requires fungal expertise to manage toxicities and significant DDIs that can limit duration of us",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 14,
      "from": 14,
      "beatId": "d61187bc-5128-49c9-99e9-db5df1690edf",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Agitate (Make it worse)",
      "beatSlug": "problem-agitate-solution-agitate-make-it-worse",
      "evidence": "The high unmet medical need in invasive aspergillosis (IA) is emphasized",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Development",
      "parentBeatSlug": "development"
    }
  ],
  "loops": [
    {
      "to": 14,
      "from": 7,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "152bbf1c-1860-4dec-b978-15c2f9ed0c98",
      "evidence": "The high unmet medical need in IA and the growing threat of IFIs are highlighted",
      "position": 0,
      "objective": "What is the cost of not addressing the growing threat of IFIs?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}